Submit an Article > Register > Login >

Annali

dell'Istituto Superiore di Sanità

Search
Vol. 56 No. 4 (2020)
Original Articles
2020-12-28
Share on

Classification of the Ibuprofen Active Pharmaceutical Ingredients by chemical patterns combining HPLC, 1H-NMR spectroscopy and Chemometrics: Traceability of legal medicines.

Authors

Mariangela Raimondo , Anna Borioni , Monica Bartolomei , Antonina Mosca , Gianluca Gostoli

Keywords: Active Pharmaceutical Ingredient (API), Ibuprofen, HPLC, 1H-NMR, Chemometrics

Abstract

Introduction. Ibuprofen is one of the widespread used non-steroidal anti-inflammatory
drugs. Ibuprofen active ingredient is manufactured in many sites located all around the
world. The aim of this paper was to classify the geographical source of ibuprofen active
pharmaceutical ingredients (APIs) from the legal market, based on chemical characteristics
and its impurity pattern and to define a geographical fingerprint.
Methods. To classify ibuprofen in different geographical groups, the chemometrics by
principal component analysis (PCA) and Cluster analysis was applied to HPLC, 1HNMR
data of twenty-four samples of APIs from approved manufacturers located in different
European and Asian countries.
Results. The PCA showed clearly two different geographical groups, based on particular
patterns of European or Indian samples; the cluster analysis showed the similarity of
group.
Conclusion. The chemometric analysis is an important tool for tracking the geographical origin of APIs. This could be useful to supplement the quality control ensuring safety of the medicinal products in legal market and dealing with the evolving changes of the illegal market.

References

  1. European Medicines Agency (EMA). ICH Topic Q 7 Good Manufacturing Practice for Active Pharmaceutical Ingredients. CPMP/ICH/365/96 01/11/2000; 2000.
  2. World Health Organization (WHO). WHO good manufacturing practices for active pharmaceutical ingredients. WHO Technical Report Series, No. 957; 2010.
  3. Beyer T, Matz M, Brinz D, Rädler O, Wolf B, Norwig J, Baumann K, Alban S, Holzgrabe U. Composition of OSCS-contaminated heparin occurring in 2008 in batches on the German market. Eur J Pharm Sci. 2010;40:297-304. DOI: 10.1016/j.ejps.2010.04.002.
  4. European Medicines Agency (EMA). CHMP Assessment Report for Medicinal Products Containing or Derived from Heparin. Under Article 5 (3) of Regulation (EC) No 726/2004.EMEA/CHMP/278280/2008; 2008.
  5. Food and Drug Administration (FDA). Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Quality; 2013.
  6. European Medicines Agency (EMA). Sartan medicines: companies to review manufacturing processes to avoid presence of nitrosamine impurities. EMA/248364/2019 Rev 1; 2019.
  8. World Health Organization (WHO). Update on Nitrosamine Impurities. EMP/RHT/Information Note_Nitrosamine impurities; 2019.
  10. European Directorate for the Quality of Medicines and HealthCare (EDQM). The EDQM’s response to nitrosamine contamination 2019; 2019.
  11. European Medicines Agency (EMA). EMA update on Metformin diabetes medicines. EMA/660975/2019; 2019.
  12. Acevska J, Stefkov G, Cvetkovikj I, Petkovska R, Kulevanova S, Cho J, Dimitrovska A. Fingerprinting of Morphine using chromatographic purity profiling and multivariate data analysis. J Pharm Biomed Anal. 2015;109:8-27. DOI: 10.1016/j.jpba.2015.02.016.
  13. Deconinck E, Cauwenbergh T, Bothy JL, Custers D, Courselle P, De Beer JO. Detection of sibutramine in adulterated dietary supplements using attenuated total reflectance-infrared spectroscopy. J Pharm Biomed Anal. 2014;100:279–283. DOI: 10.1016/j.jpba.2014.08.009.
  14. Ruggenthaler M, Grass J, Schuh W, Huber CG, Reischl RJ. Levothyroxine sodium revisited: A wholistic structural elucidation approach of new impurities via HPLC-HRMS/MS, on-line H/D exchange, NMR spectroscopy and chemical synthesis. J Pharm Biomed Anal. 2017;135:140-152. DOI: 10.1016/j.jpba.2016.12.002.
  15. Harms ZD, Shi Z, Kulkarni RA, Myers D. Characterization of Near-Infrared and Raman Spectroscopy for In-Line Monitoring of a Low-Drug Load Formulation in a Continuous Manufacturing Process. Anal Chem. 2019;91:8045-8053. DOI: 10.1021/acs.analchem.8b05002.
  16. Deconinck E, van Nederkassel AM, Stanimirova I, Daszykowski M, Bensaid F, Lees M, Martin GJ, Desmurs JR, Smeyers-Verbeke J, Vander Heyden Y. Isotopic ratios to detect infringements of patents or proprietary processes of pharmaceuticals: two case studies. J Pharm Biomed Anal. 2008;48:27-41. DOI: 10.1016/j.jpba.2008.04.023.
  17. Gilevska T, Gehre M, Richnow HH. Multidimensional isotope analysis of carbon, hydrogen and oxygen as tool for identification of the origin of Ibuprofen. J Pharm Biomed Anal. 2015;115:410–417. DOI: 10.1016/j.jpba.2015.07.030.
  18. Krakowska B, Custers D, Deconinck E, Daszykowski M, 2016. Chemometrics and the identification of counterfeit medicines-A review. J Pharm Biomed Anal. 2016;127:112-22. DOI: 10.1016/j.jpba.2016.04.016.
  19. Biancolillo A, Marini F. Chemometric Methods for Spectroscopy-Based Pharmaceutical Analysis. Front Chem. 2018;6:576. DOI: 10.3389/fchem.2018.00576.
  20. Monakhovaa YB, Holzgrabec U, Diehla BWK. Current role and future perspectives of multivariate (chemometric) methods in NMR spectroscopic analysis of pharmaceutical products. J Pharm Biomed Anal. 2018;147:580–589. DOI: 10.1016/j.jpba.2017.05.034.
  21. Calvo NL, Maggio RM, Kaufman TS. Characterization of pharmaceutically relevant materials at the solid state employing chemometrics methods. J Pharm Biomed Anal. 2018;147:538-564. DOI: 10.1016/j.jpba.2017.06.017.
  22. The Medicines Utilisation Monitoring Centre. National Report on Medicines use in Italy. Year 2018. Rome: Italian Medicines Agency, 2019.
  23. Ballabio D. A MATLAB toolbox for Principal Component Analysis and unsupervised exploration of data structure. Chemometrics and Intelligent Laboratory Systems. 2015;149 :Part B, 1-9. DOI: 10.1016/j.chemolab.2015.10.003.
  24. Remaud GS, Bussy U, Lees M, Thomas F, Desmurs JR, Jamin E, Silvestre V, Akoka S. NMR spectrometry isotopic fingerprinting: a tool for the manufacturer for tracking active pharmaceutical ingredients from starting materials to final medicines. Eur J Pharm Sci. 2013;48:464-73. DOI: 10.1016/j.ejps.2012.12.009.
  25. Gavin PF, Olsen BA, Wirth DD, Lorenz KT. A quality evaluation strategy for multi-sourced active pharmaceutical ingredient (API) starting materials. J Pharm Biomed Anal. 2006;41:1251–1259. DOI: 10.1016/j.jpba.2006.03.013

Downloads

PDF
PDF
Authors

Mariangela Raimondo - Istituto Superiore di Sanità, National Centre for the Control and Evaluation of Medicines, Chemical Medicines Unit https://orcid.org/0000-0002-6766-7948

Anna Borioni - Istituto Superiore di Sanità, National Centre for the Control and Evaluation of Medicines, Chemical Medicines Unit

Monica Bartolomei - Istituto Superiore di Sanità, National Centre for the Control and Evaluation of Medicines, Chemical Medicines Unit

Antonina Mosca - Istituto Superiore di Sanità, National Centre for the Control and Evaluation of Medicines, Chemical Medicines Unit

Gianluca Gostoli - Agenzia Italiana del Farmaco, AIFA

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright

Copyright (c) 2020 Annali dell'Istituto Superiore di Sanità

How to Cite
Raimondo, M., Borioni, A., Bartolomei, M., Mosca, A., & Gostoli, G. (2020). Classification of the Ibuprofen Active Pharmaceutical Ingredients by chemical patterns combining HPLC, 1H-NMR spectroscopy and Chemometrics: Traceability of legal medicines. Annali dell’Istituto Superiore Di Sanità, 56(4), 403–408. Retrieved from https://annali.iss.it/index.php/anna/article/view/1053
  • Abstract viewed - 570 times
  • PDF downloaded - 235 times
  • PDF downloaded - 42 times